ASH 2019 | International ABNL-MARRO trial for MDS/MPN overlap syndromes
Valeria Santini
• 7 Dec 2019
Valeria Santini, MD, University of Florence, Florence, Italy, discusses the ABNL-MARRO trial (NCT04061421), a basket study of novel therapy for untreated myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) and relapsed/refractory MDS/MPN overlap syndromes, such as chronic myelomonocytic leukemia (CMML). Beyond the primary objectives of evaluating the safety and efficacy of novel treatment combinations, this international co-operative trial will provide a novel framework for future trials in MDS/MPN and explore clinicopathological biomarkers. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
